background
upper
respiratori
tract
infect
urti
includ
rhiniti
nasopharyng
tonsil
otiti
media
om
compris
total
respiratori
infect
especi
children
therefor
effect
prevent
treatment
rti
remain
high
prioriti
worldwid
preclin
clinic
data
highlight
rational
use
effect
immunitytarget
approach
includ
target
immunis
nonspecif
immunomodul
prevent
manag
recurr
upper
rti
idea
review
summaris
current
evid
address
key
question
concern
use
conserv
immunitytarget
approach
recurr
chronic
urti
focu
paediatr
popul
health
sourc
nursingacadem
edit
medlin
clinicaltrialsgov
cochran
databas
total
articl
retriev
review
two
independ
research
focus
primari
secondari
endpoint
systemat
review
metaanalys
randomis
control
trial
use
immunitydirect
strategi
control
group
within
subpopul
larger
studi
exist
guidelin
interventionalobserv
studi
novel
applic
also
includ
result
children
particularli
suscept
rti
due
rel
immatur
immun
system
well
potenti
predispos
factor
day
care
attend
andor
toxic
environment
factor
eg
increas
pathogen
microbi
exposur
air
pollut
recurr
urti
affect
otherwis
healthi
children
lead
clinic
sequela
complic
includ
develop
chronic
condit
need
surgeri
avail
preclin
clinic
data
highlight
rational
use
effect
immunitytarget
approach
includ
target
immunis
flu
pneumococc
vaccin
nonspecif
immunomodul
bacteri
lysat
prevent
manag
recurr
croup
tonsil
otiti
media
recurr
acut
rhinosinus
chronic
rhinosinus
review
summaris
current
evid
provid
data
demonstr
immunitytarget
strategi
includ
vaccin
immunomodul
prove
effect
treatment
prevent
recurr
chronic
urti
children
feleszko
et
al
upper
respiratori
tract
infect
urti
also
known
ent
infect
includ
rhiniti
nasopharyng
tonsil
otiti
media
om
compris
total
respiratori
infect
aetiolog
urti
mostli
viral
primarili
caus
rhinoviru
hrv
parainfluenza
respiratori
syncyti
viru
rsv
influenza
adenoviru
coronaviru
upper
respiratori
tract
infect
common
autumnwint
europ
north
america
raini
season
tropic
countri
children
prone
develop
rti
immun
system
yet
fulli
matur
increas
exposur
viral
infect
day
care
attend
well
social
environment
factor
increas
risk
rti
respiratori
system
primari
target
key
air
pollut
increas
risk
acut
recurr
rti
pollut
disrupt
local
mucos
innat
immun
mechan
lead
bacteri
colonis
impair
kill
increas
allergen
permeabl
urti
associ
sequela
complic
includ
sever
lower
rti
lrti
develop
chronic
condit
need
surgeri
recurr
owe
high
morbid
mortal
healthcar
cost
effect
prevent
treatment
rti
high
prioriti
worldwid
treatment
focus
symptom
relief
antihistamin
decongest
nasal
congest
antituss
cough
although
antibiot
indic
minor
patient
often
unnecessarili
prescrib
viral
infect
effect
recent
us
report
highlight
outpati
oral
antibiot
prescript
inappropri
written
antibiot
misus
led
emerg
resist
bacteria
mean
higher
dose
advanc
gener
drug
requir
present
infect
patient
treat
adequ
owe
current
unmet
need
effect
altern
conserv
therapi
effort
refocus
toward
prevent
strategi
includ
behaviour
intervent
avoid
environment
risk
factor
passiv
smoke
highli
pollut
citi
area
vaccin
activ
target
immunis
target
medic
intervent
nonspecif
immunostimul
immunomodul
eg
bacteri
lysat
nutrit
includ
vitamin
eg
c
microel
regular
physic
activ
tabl
parent
children
recurr
rti
may
also
discuss
immunestimul
therapi
seen
advertis
herbal
eg
echinacea
homoeopath
remedi
animalderiv
product
eg
cod
liver
oil
thymu
extract
owe
signific
heterogen
lack
highqual
clinic
evid
support
mani
therapi
review
exist
immunitytarget
therapi
avail
ent
infect
children
emphasi
nonspecif
immunomodul
administ
togeth
standard
care
base
increas
nonspecif
immunoglobulin
respons
pathogen
mucos
surfac
also
activ
mucos
dendrit
cell
pattern
recognit
receptordepend
signal
review
want
highlight
emerg
evidencebas
approach
conserv
manag
common
recurr
chronic
urti
children
emphasi
role
immunomodul
human
particip
involv
develop
review
ethic
committe
institut
review
board
approv
sought
obtain
necessari
obtain
inform
consent
patient
children
recurr
sever
croup
commonli
refer
paediatr
otolaryngologist
ent
specialist
assess
exclus
underli
anatom
congenit
upper
airway
disord
croup
occur
rate
second
year
life
peak
incid
month
year
age
around
annual
clinic
emerg
depart
visit
paediatr
rti
due
croup
recurr
croup
children
typic
defin
three
episod
croup
primarili
caus
parainfluenza
virus
well
rsv
virus
gener
spread
direct
inhal
cough
sneez
contamin
hand
follow
contact
fomit
subsequ
transfer
mucosa
eye
nose
mouth
treatment
croup
depend
sever
upper
airway
obstruct
risk
rapid
deterior
patient
condit
mildtomoder
croup
typic
treat
antiinflammatori
agent
nebulis
oral
steroid
adrenalin
requir
urgent
case
sever
croup
use
system
corticosteroid
earli
diseas
process
reduc
hospitalis
rate
although
patient
still
requir
hospitalis
tonsil
common
among
children
adult
usa
sore
throat
account
outpati
visit
preval
bacteri
tonsil
among
affect
children
recurr
tonsil
children
defin
multipl
episod
acut
tonsil
year
burden
recurr
tonsil
substanti
may
lead
peritonsil
howev
overal
frequenc
magnitud
problem
recurr
tonsil
remain
unclear
treatment
tonsil
children
focus
reduc
symptom
avoid
complic
decreas
number
diseaserel
school
absenc
improv
qualiti
life
accord
clinic
practic
guidelin
firstlin
treatment
bacteri
tonsil
narrowspectrum
antibiot
eg
penicillin
howev
european
countri
includ
germani
uk
netherland
recommend
antibiot
certain
highrisk
patient
wide
accept
indic
tonsillectomi
children
least
seven
welldocu
clinic
signific
adequ
treat
sore
throat
defin
acut
pharyng
tonsil
acut
exud
tonsil
preced
year
least
five
episod
preced
year
least
three
episod
preced
year
surgeri
also
consid
episod
disabl
prevent
normal
function
approxim
children
age
less
year
treat
aom
experi
recurr
within
month
symptom
last
day
may
also
predict
recurr
treatment
approach
aom
depend
factor
patient
age
sever
sign
symptom
malform
cystic
fibrosi
ciliari
dyskinesia
need
exclud
greater
patientpar
educ
highlight
import
avoid
passiv
smoke
signific
factor
impair
mucos
immun
breastfeed
children
age
less
year
invas
intervent
insert
tympanostomi
tube
may
requir
children
recurr
aom
one
follow
age
less
year
underli
medic
condit
predispos
patient
recurr
comorbid
condit
associ
development
languag
delay
howev
gener
lack
consensu
regard
role
surgeri
aom
parent
children
recurr
aom
usual
anxiou
pursu
surgic
treatment
option
often
seek
complementari
remedi
epo
group
defin
acut
rhinosinus
ar
sudden
onset
two
symptom
last
week
howev
older
classif
term
subacut
sinus
propos
repres
tempor
progress
symptom
week
contemporarili
defin
postvir
ar
although
chronic
rhinosinus
cr
defin
persist
sinu
inflamm
least
week
epo
group
feel
separ
term
describ
patient
prolong
ar
necessari
exacerb
cr
appropri
europ
children
urti
progress
postvir
ar
mani
experi
recurr
point
preval
estim
cr
preval
vari
significantli
worldwid
partli
relat
differ
diagnost
criteria
use
eg
symptombas
diagnosi
vs
inclus
object
rhinoscopi
imag
find
usa
preval
cr
rang
variou
eu
countri
averag
estim
south
america
caribbean
similar
rang
differenti
recurr
ar
cr
difficult
reli
complet
resolut
symptom
episod
patient
recurr
episod
ar
may
repres
distinct
clinic
phenotyp
patient
assess
underli
risk
factor
allergi
immunodefici
cystic
fibrosi
anatom
abnorm
consider
imag
endoscop
evalu
nasalparanas
mucosa
first
interfac
inhal
toxin
pollut
environment
factor
thought
import
caus
transit
ar
cr
well
trigger
symptom
exacerb
cr
exampl
signific
associ
passiv
smoke
sinus
care
analysi
underli
defect
perform
exampl
anatom
abnorm
immunodefici
cochran
metaanalysi
evalu
intranas
steroid
cr
children
effect
diseas
sever
although
symptomat
improv
nasal
blockag
rhinorrhoea
loss
sens
smell
facial
pain
observ
base
observ
recommend
intranas
steroid
categori
iaa
option
children
recurr
ar
andor
cr
immunis
lead
increas
host
resist
capabl
decreas
incid
acut
respiratori
diseas
rapid
emerg
resist
bacteria
jeopardis
efficaci
antibiot
inde
decreas
use
antibiot
consid
top
prioriti
healthcar
author
around
world
avoid
consequ
effect
overus
increas
antibiot
resist
mucosa
microbiom
impair
new
treatment
prevent
modal
respiratori
infect
expect
welcom
modul
human
immun
system
becom
increasingli
relev
gener
infecti
diseas
allergi
gastroenterolog
also
disciplin
oncolog
entrel
disord
review
discuss
clinic
evid
support
use
select
immunomodulatori
strategi
children
specif
ent
condit
howev
remain
barrier
widespread
use
therapi
exampl
avail
data
specif
ent
infect
remain
spars
although
evid
around
prevent
gener
rti
robust
ideal
new
studi
perform
specif
ent
infect
children
order
increas
evid
base
support
treatment
recommend
addit
accord
avail
metaanalysi
mani
commerci
avail
product
demonstr
moder
effect
import
gener
highqual
research
data
use
immunomodulatori
strategi
patient
specif
urti
upper
respiratori
tract
diseas
author
would
like
thank
andrew
jone
phd
mudskipp
busi
ltd
excel
editori
assist
dr
stefania
ballarini
coordin
initi
discuss
prepar
manuscript
